Application Note: Ex vivo phenotyping and potency monitoring of CD19 CAR T cells
5 November 2020

The development of cell-mediated immunotherapies has revolutionized cancer research as well as the study of the immune system. One of the most promising types of cell therapy involves the genetic engineering of novel chimeric antigen receptor (CAR) T cells to target cancer cells. To efficiently determine optimal CAR construction, researchers must develop a robust screening protocol to identify the ideal parent T cell populations and evaluate their cell killing potency. In this application note a workflow using a combination of the Agilent xCELLigence RTCA analyzer and Agilent NovoCyte Quanteon flow cytometer to thoroughly evaluate and characterize CAR T cells is described.